EGI
SRPT icon

EAM Global Investors’s Sarepta Therapeutics SRPT Stock Holding History

EAM Global Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,103
Closed -$4.01M – 119
2023
Q1 		$4.01M Buy
29,103
+14,786
+103% +$1.92M 1.13% 54
2022
Q4 		$1.86M Sell
14,317
-6,156
-30% -$713K 0.48% 91
2022
Q3 		$2.26M Buy
+20,473
New +$2.06M 0.6% 51

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Global Investors's SRPT Position: Q2 2023 in Review

EAM Global Investors sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 29,103 shares — an estimated $4.01M sold.

EAM Global Investors first reported a position in SRPT in Q3 2022 and held it in 3 quarters. The position peaked at $4.01M in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • EAM Global Investors reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • EAM Global Investors sold 29,103 Sarepta Therapeutics shares in Q2 2023, an estimated $4.01M.
  • EAM Global Investors first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 3 quarters.
  • EAM Global Investors's Sarepta Therapeutics position peaked at $4.01M in Q1 2023.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on EAM Global Investors's 13F filing for Q2 2023, filed 11 Aug 2023.